UCB to present 23 EADV 2026 abstracts spanning atopic dermatitis, HS and psoriasis studies

By Public Technologies
  • UCB SA outlined plans to present 23 dermatology-related abstracts at EADV 2026 in Vienna.
  • Data will span clinical trials, long-term extensions, head-to-head comparisons, real-world cohorts, and registry analyses across several immune-mediated diseases.
  • Across datasets, results point to earlier disease control potentially improving long-term outcomes, supporting a strategic push toward earlier intervention.
  • UCB also flagged new atopic dermatitis findings as part of its ongoing investment in differentiated dermatology and immunology research.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.